KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Assets (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Assets data on record, last reported at $784.1 million in Q4 2025.

  • For Q4 2025, Assets fell 37.79% year-over-year to $784.1 million; the TTM value through Dec 2025 reached $784.1 million, down 37.79%, while the annual FY2025 figure was $784.1 million, 37.79% down from the prior year.
  • Assets reached $784.1 million in Q4 2025 per PACB's latest filing, down from $803.2 million in the prior quarter.
  • Across five years, Assets topped out at $2.0 billion in Q3 2021 and bottomed at $784.1 million in Q4 2025.
  • Average Assets over 5 years is $1.5 billion, with a median of $1.7 billion recorded in 2023.
  • Peak YoY movement for Assets: skyrocketed 577.33% in 2021, then tumbled 48.45% in 2025.
  • A 5-year view of Assets shows it stood at $2.0 billion in 2021, then fell by 11.95% to $1.8 billion in 2022, then dropped by 1.19% to $1.7 billion in 2023, then fell by 27.81% to $1.3 billion in 2024, then crashed by 37.79% to $784.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $784.1 million in Q4 2025, $803.2 million in Q3 2025, and $825.5 million in Q2 2025.